RE:RE:RE:RE:RE:Website Subtle wording changes on new slide deck makes me wonder just how insignificant the Abbvie deal is and the timing of a product launch. The June 2022 NR said Abbvie licensed 1067 and a related family of compounds. New slide deck says Abbvie licensed 1067 and a library/family of dark spot correctors. The latter suggests limited additional compounds beyond 1067. And it also makes me wonder if Abbvie will test other dark spot correctors from Sirona before launching a product.
June 13, 2022 -- Sirona Biochem Corp. is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 and related family of compounds.